Cannabis and the Opioid Crisis: Evidence, Promise, and Caution
Can cannabis reduce opioid use? What the research says — and what it doesn't
The opioid crisis has killed hundreds of thousands of Americans. Cannabis has been proposed as an opioid substitute or adjunct that could reduce opioid use and overdose deaths. This article examines the evidence — which is more complex and less definitive than headlines suggest.
The Opioid Crisis Context
The opioid overdose crisis has claimed over 500,000 American lives since 1999. Prescription opioids, heroin, and illicitly manufactured fentanyl have driven successive waves of overdose deaths. In this context, any intervention that could reduce opioid use or overdose risk attracts enormous attention. Cannabis has been proposed as both an opioid substitute (replacing opioids for pain management) and an opioid adjunct (allowing lower opioid doses while maintaining pain control).
The Ecological Evidence: State-Level Studies
The most widely cited evidence for cannabis-opioid substitution comes from ecological studies — analyses of population-level data. A landmark 2014 study by Bachhuber et al. found that states with medical cannabis laws had 24.8% lower opioid overdose mortality rates than states without such laws. Several subsequent studies found similar associations.
However, more recent and methodologically rigorous analyses have challenged these findings. A 2019 study by Shover et al. found that the association between medical cannabis laws and reduced opioid mortality reversed after 2010 — states with medical cannabis laws actually had higher opioid mortality in later years, likely because the opioid crisis evolved (driven by illicit fentanyl) in ways unrelated to cannabis policy. Ecological studies cannot establish causation and are susceptible to confounding by many state-level factors.
Individual-Level Evidence: Surveys and Observational Studies
Survey studies consistently find that medical cannabis patients report reducing or eliminating opioid use after starting cannabis. A 2017 survey by Boehnke et al. found that 64% of medical cannabis patients reported using cannabis as a substitute for prescription drugs, with opioids being the most commonly substituted drug class. A 2019 survey found that 53% of medical cannabis patients reported reducing opioid use.
These findings are compelling but limited by selection bias — patients who choose to use cannabis may be more motivated to reduce opioids regardless of cannabis's pharmacological effects. Observational studies cannot rule out confounding. The patients who successfully substitute cannabis for opioids may be those with less severe pain or less severe opioid dependence.
RCT Evidence: Limited but Promising
Randomized controlled trial evidence for cannabis-opioid interactions is limited. A 2021 RCT by Aviram et al. found that adding cannabis to opioid therapy in chronic pain patients did not reduce opioid dose but did improve pain scores and quality of life. A 2018 study found that vaporized cannabis added to opioid therapy produced greater pain relief than opioids alone, suggesting an additive analgesic effect.
For opioid withdrawal specifically, CBD has shown promise. A 2019 RCT by Hurd et al. found CBD (400–800mg) significantly reduced cue-induced craving and anxiety in abstinent heroin users — a key mechanism of relapse. This suggests CBD may be useful as an adjunct to opioid use disorder treatment, though it is not a replacement for evidence-based treatments (methadone, buprenorphine).
The Risks of Cannabis-Opioid Substitution
The narrative of cannabis as an opioid substitute carries risks. Cannabis is not a proven treatment for opioid use disorder — it does not prevent withdrawal, reduce cravings (except CBD in specific contexts), or block opioid receptors. Encouraging opioid-dependent patients to substitute cannabis without medical supervision could lead to undertreated withdrawal and relapse to opioids.
Cannabis and opioids also have pharmacodynamic interactions: both are CNS depressants, and combining them increases sedation and potentially respiratory depression risk. The combination of cannabis and opioids in patients with respiratory conditions (COPD, sleep apnea) requires particular caution.
The Bottom Line
The evidence that cannabis can reduce opioid use in some patients is suggestive but not definitive. The strongest evidence is for cannabis as an analgesic adjunct — adding cannabis to opioid therapy may improve pain control and quality of life, potentially allowing lower opioid doses. The evidence for cannabis as a complete opioid substitute is weaker and primarily observational.
Cannabis is not a solution to the opioid crisis. The crisis is driven primarily by illicit fentanyl, and cannabis cannot address fentanyl overdose risk. Evidence-based opioid use disorder treatments (methadone, buprenorphine, naltrexone) remain the standard of care. Cannabis may have a role as an adjunct in carefully selected patients under medical supervision — but it should not be positioned as a replacement for proven treatments.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making treatment decisions. See our editorial standards.